Psoriatic arthritis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Psoriatic arthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Psoriatic arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Psoriatic arthritis: Overview
Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.
'Psoriatic arthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic arthritis pipeline landscape is provided which includes the disease overview and Psoriatic arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Psoriatic arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriatic arthritis Emerging Drugs
Further product details are provided in the repor
Psoriatic arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriatic arthritis drugs segregated based on following parameters that define the scope of the report, such as:
Psoriatic arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic arthritis drugs.
Psoriatic arthritis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Psoriatic arthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Psoriatic arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Psoriatic arthritis: Overview
Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.
'Psoriatic arthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic arthritis pipeline landscape is provided which includes the disease overview and Psoriatic arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic arthritis.
This segment of the Psoriatic arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriatic arthritis Emerging Drugs
- Tildrakizumab: Sun Pharma Global
- BMS-986165: Bristol-Myers Squibb
- AbGn-168H: AbGenomics
- Apremilast: 3SBio
Further product details are provided in the repor
Psoriatic arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriatic arthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Psoriatic arthritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Psoriatic arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic arthritis drugs.
Psoriatic arthritis Report Insights
- Psoriatic arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Psoriatic arthritis drugs?
- How many Psoriatic arthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic arthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriatic arthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Psoriatic arthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sun Pharma Global
- UCB Biopharma
- Pfizer
- Bristol-Myers Squibb
- AbGenomics
- Boehringer Ingelheim
- Affibody
- AltruBio
- Synact Pharma
- NeuClone
- 3SBio
- Qyuns Therapeutics
- Kangpu Biopharmaceuticals
- Alpine Immune Sciences
- Avotres
- Xbrane Biopharma
- XBiotech
- Evelo
- Luye Pharma Group
- Levolta Pharmaceuticals
- DNX Biopharmaceuticals
- Mycenax Biotech
- Tildrakizumab
- Bimekizumab
- PF-06700841
- BMS-986165
- AbGn-168H
- BI 730357
- Izokibep
- Neihulizumab
- AP1189
- NeuLara
- Apremilast
- QX 002N
- KPG-612
- ALPN 101
- AVT001
- Xcimzane
- RHE 70202
- EDP1815
- DNX 514
- DNX 114
Introduction
Executive Summary
Psoriatic arthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Psoriatic arthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Psoriatic arthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Psoriatic arthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tildrakizumab: Sun Pharma Global
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS-986165: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Apremilast: 3SBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery stage Products
Comparative Analysis
ALPN 101: Alpine Immune Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Psoriatic arthritis Key Companies
Psoriatic arthritis Key Products
Psoriatic arthritis- Unmet Needs
Psoriatic arthritis- Market Drivers and Barriers
Psoriatic arthritis- Future Perspectives and Conclusion
Psoriatic arthritis Analyst Views
Psoriatic arthritis Key Companies
Appendix
Executive Summary
Psoriatic arthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Psoriatic arthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Psoriatic arthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Psoriatic arthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tildrakizumab: Sun Pharma Global
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS-986165: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Apremilast: 3SBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery stage Products
Comparative Analysis
ALPN 101: Alpine Immune Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Psoriatic arthritis Key Companies
Psoriatic arthritis Key Products
Psoriatic arthritis- Unmet Needs
Psoriatic arthritis- Market Drivers and Barriers
Psoriatic arthritis- Future Perspectives and Conclusion
Psoriatic arthritis Analyst Views
Psoriatic arthritis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Psoriatic arthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Psoriatic arthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Psoriatic arthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Psoriatic arthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
